Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit.
| Brand name | QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE |
| Generic name | QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE |
| Active ingredient(s) | HYDROCHLOROTHIAZIDE, QUINAPRIL HYDROCHLORIDE |
| Distributed by / for | Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520 |
| NDC | 65862-162-90 |
| Full product label | Quinapril and Hydrochlorothiazide Tablets, USP 20mg/12.5mg, 90 Tablets bottles Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520, Made in India, NDC 65862-162-90 |
| Recalling firm | Aurobindo Pharma USA Inc. |
| Distribution | Nationwide |
| Quantity | 9504 bottles |
| Recall initiated | 2022-10-05 |
| Report date | 2022-11-02 |
| Recall completed | — |
| Recall number | D-0021-2023 |
| Classification | Class II |
| FDA status | Completed |
| Origin on file | East Windsor NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗